Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...

In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...

Zipalertinib showed a 35% overall response rate in EGFR exon 20 mutated NSCLC, with notable CNS activity and a favorable safety profile. NeoADAURA trial highlighted the feasibility of neoadjuvant EGFR ...

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

An international team confirms in a pioneering phase 3 clinical trial the decisive role of the time of day on the success of anti-tumour immunotherapies.

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program. In Japan, Optune ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...